LYRA, US55234L2043

Lyra Therapeutics stock falls 3.50 percent in OTC trading

Published on 10/05/2026 at 18:21 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Lyra Therapeutics stock stood at USD 0.14 on October 5, 2026, while OTC market capitalization was USD 0.3 million. Q1 revenue was USD 7,000 versus USD 246,000 consensus.

LYRA, US55234L2043, Illustration mit AI erstellt.

Lyra Therapeutics stock (ISIN US55234L2043) was trading at USD 0.14 on OTC Markets at 10:42 a.m. ET on October 5, 2026, down 3.50 percent from the USD 0.15 prior close. The company is now valued at USD 0.3 million by the market, making its latest operating figures and listing status central to the investment case.

Revenue trails quarterly consensus

According to Investing.com, Lyra's earnings panel for the quarter ended March 31, 2026 lists revenue of USD 7,000 against a consensus estimate of USD 246,000. That comparison places reported revenue USD 239,000 below the published estimate.

The same Investing.com panel lists earnings per share of negative USD 3.91 against a consensus estimate of negative USD 0.24 for Q1 2026. The figures point to a company whose near-term financial profile remains dominated by development spending rather than product revenue.

Nasdaq history shapes the risk

Lyra's investor-relations page describes a clinical-stage biotechnology company developing long-acting anti-inflammatory nasal inserts for chronic rhinosinusitis. Its LYR-210 and LYR-220 candidates are designed to deliver six months of mometasone furoate therapy through a single in-office procedure, according to Lyra Therapeutics.

The listing structure changed materially in 2026. EdgeChat reports that Nasdaq suspended LYRA trading on March 17, 2026, after Lyra suspended development of its lead candidate, with delisting procedures commencing in March. Current OTC trading therefore represents a different market setting from the company's earlier Nasdaq listing.

Stock trades below its yearly high

The October 5 quote places LYRA at USD 0.14, with a session high and low of USD 0.14 and volume of 100 shares. The daily move of negative 3.50 percent contrasts with the company's USD 0.15 prior close and shows the limited liquidity surrounding the OTC quotation.

For investors, the key tension is visible in the numbers: a USD 0.3 million market capitalization sits alongside USD 7,000 of quarterly revenue and negative USD 3.91 quarterly earnings per share. The biotechnology platform remains tied to clinical development, while the trading venue and Nasdaq history add a separate market-structure risk.